Challenges in systematic reviews that assess treatment harms

Annals of Internal Medicine

Volumn 142, Issue 12 II, 2005, Pages 1090-1099

  Chou, Roger ^a   Helfand, Mark ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANOREXIGENIC AGENT; CELECOXIB; DICLOFENAC; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR;

ANGIONEUROTIC EDEMA; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; EMPIRICISM; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; REYE SYNDROME; RISK BENEFIT ANALYSIS; SCLERODERMA; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES; VAGINA CARCINOMA; VALIDATION PROCESS;

EID: 20544439606     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-142-12_part_2-200506211-00009     Document Type: Review

References (111)

1. Loke YK, Price D, Herxheimer A. Including adverse effects in your review. Cochrane Adverse Effects Subgroup. Accessed at www.dsru.org/wwwboard /latestdraft.pdf on 2 August 2004.
2. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. GRADE Working Group. BMJ. 2004;328:1490. [PMID: 15205295]
3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-9. [PMID: 11072960]
4. Cuervo LG, Clarke M. Balancing benefits and harms in health care [Editorial]. BMJ. 2003;327:65-6. [PMID: 12855496]
5. Ernst E, Pittler MH. Assessment of therapeutic safety in systematic reviews: literature review. BMJ. 2001;323:546. [PMID: 11546700]
6. Papanikolaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med. 2004;117:582-9. [PMID: 15465507]
7. Derry S, Kong Loke Y, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Method. 2001;1:7. [PMID: 11591220]
8. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-8. [PMID: 15545678]
9. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Method. 2004;4:19. [PMID: 15260887]
10. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ. 1998;316:140-4. [PMID: 9462324]
11. Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage. 1999;18:427-37. [PMID: 10641469]
12. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry. 2004;161: 1692-7. [PMID: 15337661]
13. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess. 2003;7:1-76. [PMID: 12583822]
14. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-43. [PMID: 11242428]
15. Moore SW. An overview of drug development in the United States and current challenges. South Med J. 2003;96:1244-55; quiz 1256. [PMID: 14696877]
16. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005;365:82-93. [PMID: 15639683]
17. Ray WA. Population-based studies of adverse drug effects. N Engl J Med. 2003;349:1592-4. [PMID: 14573730]
18. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet. 2000;356:1339-43. [PMID: 11073036]
19. Vandenbroucke JP. Benefits and harms of drug treatments [Editorial]. BMJ. 2004;329:2-3. [PMID: 15231587]
20. Dieppe P, Bartlett C, Davey P, Doyal L, Ebrahim S. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ. 2004;329: 31-4. [PMID: 15231619]
21. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356:1228-31. [PMID: 11072941]
22. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341-5. [PMID: 15110490]
23. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178:234-41. [PMID: 11230034]
24. Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Ann Intern Med. 2005;142:1066-72.
25. Lee S. Statistical review. Center for Drug Evaluation and Research. Accessed at www.fda.gov/cder/foi/nda/2002/21-042S007_Vioxx_statr.pdf on 28 February 2005.
26. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343:1520-8, 2 p following 1528. [PMID: 11087881]
27. Witter J. Medical review part 1. Center for Drug Evaluation and Research. Accessed at www.fda.gov/cder/foi/nda/2002/20-998S009_Celebrex_medr_P1 .pdf on 28 February 2005.
28. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284: 1247-55. [PMID: 10979111]
29. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [Letter]. JAMA. 2001;286:2398-400. [PMID: 11712925]
30. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib [Letter]. JAMA. 2001;286:2398; author reply 2399-400. [PMID: 11712924]
31. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ. 2004;328:39-41. [PMID: 14703546]
32. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363:1728-31. [PMID: 15158638]
33. Black N. Evidence-based surgery: a passing fad? World J Surg. 1999;23:789-93. [PMID: 10415204]
34. Etminan M, Samii A. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacotherapy. 2004;24:964-9. [PMID: 15338844]
35. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22:2064-70. [PMID: 15121324]
36. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-81. [PMID: 5549830]
37. Ray JG. Evidence in upheaval: incorporating observational data into clinical practice. Arch Intern Med. 2002;162:249-54. [PMID: 11822916]
38. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47:749-54. [PMID: 10366179]
39. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363:1724-7. [PMID: 15158637]
40. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329:44-7. [PMID: 15231627]
41. Mulrow CD, Williams JW, Trivedi M, Chiquette E, Aguilar C, Cornell JE. Treatment of depression: newer pharmacotherapies. Evidence Report/Technology Assessment No. 7 (Prepared by San Antonio Evidence-based Practice Center based at the University of Texas Health Science Center at San Antonio under contract 290-97-0012). Rockville, MD: Agency for Health Care Policy and Research; February 1999. AHCPR publication no. 99-E014.
42. Shekelle P, Hardy M, Morton SC, Maglione M, Suttorp M, Roth E, et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Evidence Report/Technology Assessment No. 76 (Prepared by Southern California-RAND Evidence-based Practice Center under contract 290-97-0001). Rockville, MD: Agency for Healthcare Research and Quality; March 2003. AHRQ publication no. 03-E022.
43. Goudas L, Carr DB, Bloch R, Balk E, Ioannidis JPA, Terrin N, et al. Management of cancer pain. Evidence Report/Technology Assessment No. 35 (Prepared by New England Medical Center Evidence-based Practice Center under contract 290-97-0019). Rockville, MD: Agency for Healthcare Research and Quality; October 2001. AHRQ publication no. 02-E002.
44. Meenan RT, Saha S, Swarztrauber K, Krages KP, O'Keefe-Rosetti M, McDonagh M, et al. Effectiveness and cost-effectiveness of echocardiography and carotid imaging in the management of stroke. Evidence Report/Technology Assessment No. 49 (Prepared by Oregon Health Sciences University Evidence-based Practice Center under contract 290-97-0018). Rockville, MD: Agency for Healthcare Research and Quality; July 2002. AHRQ publication no. 02-E022.
45. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess. 1998;2:i-iv, 1-124. [PMID: 9793791]
46. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342: 1887-92. [PMID: 10861325]
47. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821-30. [PMID: 11497536]
48. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-86. [PMID: 10861324]
49. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29:804-12. [PMID: 11950025]
50. Bond R, Rerkasem K, Rothwell PM. Systematic review of the risks of carotid endarterectomy in relation to the clinical indication for and timing of surgery. Stroke. 2003;34:2290-301. [PMID: 12920260]
51. Lawlor DA, Juni P, Ebrahim S, Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol. 2003;56:155-63. [PMID: 12654410]
52. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003-14. [PMID: 12706690]
53. Jefferson T, Price D, Demicheli V, Bianco E, European Research for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. Vaccine. 2003; 21:3954-60. [PMID: 12922131]
54. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-45. [PMID: 9042847]
55. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364: 2021-9. [PMID: 15582059]
56. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-9. [PMID: 8256394]
57. Wennberg JE, Roos N, Sola L, Schori A, Jaffe R. Use of claims data systems to evaluate health care outcomes. Mortality and reoperation following prostatectomy. JAMA. 1987;257:933-6. [PMID: 3543419]
58. Ettinget B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care. 1998;4:1377-82. [PMID: 10338731]
59. Etminan M. Pharmacoepidemiology II: the nested case-control study-a novel approach in pharmacoepidemiologic research. Pharmacotherapy. 2004;24: 1105-9. [PMID: 15460170]
60. Lindbloom EJ, Ewigman BG, Hickner JM. Practice-based research networks: the laboratories of primary care research. Med Care. 2004;42:11145-9. [PMID: 15026664]
61. Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf. 2004;27:871-81. [PMID: 15366975]
62. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ. 2005;330:389. [PMID: 15718538]
63. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005;330:385. [PMID: 15718537]
64. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330:396. [PMID: 15718539]
65. Aronson JK, Derry S, Loke YK. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol. 2002;16:49-56. [PMID: 11903512]
66. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol. 2004;57:616-21. [PMID: 15089815]
67. Venning GR. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed). 1983;286:458-60. [PMID: 6401562]
68. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-20. [PMID: 11980521]
69. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol. 2001;57:89-91. [PMID: 11372600]
70. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA. 2004;292:2643-6. [PMID: 15572722]
71. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA. 2004;292:2622-31. [PMID: 15572720]
72. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13. [PMID: 8689816]
73. Food and Drug Administration Center for Drug Evaluation and Research. FDA public health advisory for Crestor (rosuvastatin). Accessed at www.fda.gov/cder/drug/advisory/crestor.htm on 1 March 2005.
74. Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94:882-8. [PMID: 15464670]
75. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-13. [PMID: 9746022]
76. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: 8721797]
77. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-60. [PMID: 10493204]
78. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in metaanalyses of randomized controlled trials. JAMA. 2002;287:2973-82. [PMID: 12052127]
79. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377-84. [PMID: 9764259]
80. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712-6. [PMID: 12956787]
81. Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. Khan SK, ter Riet G, Glanville J, Sowden AJ, Klejnen J, eds. York, United Kingdom: Univ of York; 2001.
82. Saunders LD, Soomro GM, Buckingham J, Jamtvedt G, Raina P. Assessing the methodological quality of nonrandomized intervention studies. West J Nurs Res. 2003;25:223-37. [PMID: 12666645]
83. West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, et al. Systems to rate the strength of scientific evidence. Evidence Report/Technology Assessment No. 47 (Prepared by Research Triangle Institute-University of North Carolina Evidence-based Practice Center under contract 290-97-0011). Rockville, MD: Agency for Healthcare Research and Quality; April 2002. AHRQ publication no. 02-E016.
84. Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L. Do the findings of case series studies vary significantly according to methodological characteristics? Health Technol Assess. 2005;9:iii-iv, 1-146. [PMID: 15588556]
85. Rothwell PM, Slattery J, Warlow CP. A systematic review of the risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Stroke. 1996;27:260-5. [PMID: 8571420]
86. Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F. False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol. 1994;38:401-4. [PMID: 7893579]
87. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. Br Med J (Clin Res Ed). 1982;284:249-52. [PMID: 6799125]
88. Mulrow C, Lawrence V, Ackermann R, Ramirez G, Morbidoni L, Aguilar C, et al. Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment No. 20 (Prepared by San Antonio Evidence-based Practice Center based at the University of Texas Health Science Center at San Antonio and the Veterans Evidence-based Research, Dissemination, and Implementation Center, a Veterans Affairs Health Services Research and Development Center of Excellence, under contract 290-97-0012). Rockville, MD: Agency for Healthcare Research and Quality; October 2000. AHRQ publication no. 01-E023.
89. Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, et al. Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evidence Report/Technology Assessment No. 21 (Prepared by San Antonio Evidence-based Practice Center based at the University of Texas Health Science Center at San Antonio and the Veterans Evidence-based Research, Dissemination, and Implementation Center, a Veterans Affairs Health Services Research and Development Center of Excellence, under contract 290-97-0012). Rockville, MD: Agency for Healthcare Research and Quality; October 2000. AHRQ publication no. 01-E025.
90. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664-9. [PMID: 9303497]
91. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46: 1323-30. [PMID: 8229110]
92. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. [PMID: 7249508]
93. Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm. 1986;43:1709-14. [PMID: 3752106]
94. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123-30. [PMID: 11124828]
95. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331-6. [PMID: 8229111]
96. Aronson JK. Anecdotes as evidence [Editorial]. BMJ. 2003;326:1346. [PMID: 12816800]
97. Martin RC 2nd, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg. 2002;235:803-13. [PMID: 12035036]
98. Lau J, Balk E, Rothberg M, Ioannidis JP, DeVine D, Chew P, et al. Management of clinically inapparent adrenal mass. Evidence Report/Technology Assessment No. 56 (Prepared by New England Medical Center Evidence-based Practice Center under contract 290-97-0019). Rockville, MD: Agency for Healthcare Research and Quality; May 2002. AHRQ publication no. 02-E014.
99. Cuervo LG, Aronson JK. The road to health care [Editorial]. BMJ. 2004; 329:1-2. [PMID: 15231586]
100. Smith LA, Moore RA, McQuay HJ, Gavaghan D. Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. BMC Med Res Methodol. 2001;1:1. [PMID: 11231885]
101. Rosendaal FR. Bridging case-control studies and randomized trials. Curr Control Trials Cardiovasc Med. 2001;2:109-110. [PMID: 11806781]
102. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ. 2003;327:616-8. [PMID: 12969936]
103. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. [PMID: 10789670]
104. Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA. 1999;281:8304. [PMID: 10071005]
105. McPherson K, Hemminki E. Synthesising licensing data to assess drug safety. BMJ. 2004;328:518-20. [PMID: 14988197]
106. Mulrow CD, Chiquette E, Ferrer RL, Sibai BM, Stevens KR, Harris M, et al. Management of chronic hypertension during pregnancy. Evidence Report/Technology Assessment No. 14 (Prepared by San Antonio Evidence-based Practice Center based at the University of Texas Health Science Center at San Antonio under contract 290-97-0012). Rockville, MD: Agency for Healthcare Research and Quality; August 2000. AHRQ publication no. 00-E011.
107. Dickersin K. Systematic reviews in epidemiology: why are we so far behind? Int J Epidemiol. 2002;31:6-12. [PMID: 11914282]
108. Ross SD. Drug-related adverse events: a readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med. 2001;161:1041-6. [PMID: 11322836]
109. Mann RD. Prescription-event monitoring-recent progress and future horizons. Br J Clin Pharmacol. 1998;46:195-201. [PMID: 9764958]
110. Schunemann HJ, Best D, Vist G, Oxman AD. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169:677-80. [PMID: 14517128]
111. Petticrew M. Why certain systematic reviews reach uncertain conclusions. BMJ. 2003;326:756-8. [PMID: 12676848]